Metastatic Pancreatic Cancer Pipeline Insight 2025: Driving Innovation in One of the Deadliest Cancers | DelveInsight

DelveInsight's "Metastatic Pancreatic Cancer (MPC) - Pipeline Insight, 2025" report offers an in-depth analysis of the dynamic and challenging therapeutic landscape of metastatic pancreatic cancer, one of the most aggressive and fatal malignancies globally. With over 25+ active candidates in clinical and preclinical development, the MPC pipeline is advancing rapidly with a focus on immunotherapy, targeted agents, and next-generation chemotherapy combinations.

Innovative therapies in development include KRAS inhibitors, DNA damage response modulators (DDR), and immune checkpoint inhibitors tailored for pancreatic tumor microenvironments. Notable candidates such as Adagrasib (Mirati Therapeutics), BXCL701 (BioXcel Therapeutics), and Motixafortide (BioLineRx) are showing promise in early- to mid-stage trials. These drugs target key pathways like KRAS G12C, TGF-β, and inflammasome activation, aiming to overcome resistance to standard chemotherapy regimens like FOLFIRINOX or gemcitabine+nab-paclitaxel.

Leading biopharmaceutical companies such as Rafael Pharmaceuticals, AstraZeneca, Celgene/BMS, Oncolytics Biotech, Targovax, and ImmunityBio are advancing diverse approaches, including oncolytic viruses, cancer vaccines, antibody-drug conjugates (ADCs), and cell therapies. Many candidates have received orphan drug, fast track, or breakthrough therapy designations from the FDA, reflecting the urgent unmet need in this space.

The report covers detailed profiles of key assets by mechanism of action, clinical phase, biomarker strategies, and ongoing global trials. It also highlights combination strategies designed to reprogram the immunosuppressive tumor microenvironment, improve drug delivery, and extend survival.

As the metastatic pancreatic cancer space evolves, the growing pipeline holds promise to shift the current dismal prognosis. With emerging precision therapies and synergistic combinations, 2025 could mark a pivotal point toward better outcomes and prolonged survival for MPC patients.

Interested in learning more about the current treatment landscape and the key drivers shaping the metastatic pancreatic cancer pipeline? Click here: https://www.delveinsight.com/report-store/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Metastatic Pancreatic Cancer Pipeline Report
• DelveInsight's metastatic pancreatic cancer pipeline analysis depicts a strong space with 25+ active players working to develop 25+ pipeline drugs for metastatic pancreatic cancer treatment.
• The leading metastatic pancreatic cancer companies include Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others are evaluating their lead assets to improve the metastatic pancreatic cancer treatment landscape.
• Key metastatic pancreatic cancer pipeline therapies in various stages of development include Fuzuloparib, Glufosfamide - Eleison Pharmaceuticals, SBP 101, SGT-53, MDB 401 B, Motixafortide, Epacadostat, Retifanlimab, Roducitabine, Olaratumab, RX 0201, Masitinib, Simurosertib, and others.
• In July 2025, Arcus Biosciences announced that the FDA granted orphan drug designation to quemliclustat, its investigational CD73 inhibitor, for the treatment of pancreatic cancer.
• In June 2025, Revolution Medicines announced that the FDA granted Breakthrough Therapy Designation to daraxonrasib for treating previously treated metastatic pancreatic cancer with KRAS G12 mutations.
• In March 2025, PEP-Therapy announced that the FDA granted Orphan Drug designation to its lead product, PEP-010, for pancreatic cancer treatment.
• In February 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) status to nogapendekin alfa (Anktiva) and CAR-NK (PD-L1 t-haNK) for their potential to reverse lymphopenia in patients undergoing chemotherapy/radiotherapy and to treat metastatic pancreatic cancer.
• In February 2025, Alligator Bioscience announced the successful completion of its End of Phase 2 (EOP2) interaction with the FDA, paving the way for a Phase 3 trial in 2025. The trial will test mitazalimab as a first-line treatment for metastatic pancreatic cancer in combination with mFOLFIRINOX.

Request a sample and discover the recent breakthroughs happening in the metastatic pancreatic cancer pipeline landscape at https://www.delveinsight.com/report-store/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Metastatic Pancreatic Cancer Overview
Pancreatic cancer, also known as pancreatic ductal carcinoma, originates from the cells lining the pancreatic ducts and is the fourth leading cause of cancer-related deaths in the United States. The 5-year survival rate ranges from 5% to 15%, with an overall survival rate of just 6%. Surgery remains the only potential cure, but only about 20% of cases are eligible for surgical removal at diagnosis.

For metastatic pancreatic cancer, surgery is primarily used to manage symptoms like pain, jaundice, or gastric outlet obstruction, rather than to cure the disease. Radiation therapy may also be employed for symptom relief. Since metastatic cancer has spread to other organs, surgery cannot eliminate it.
Find out more about metastatic pancreatic cancer medication at https://www.delveinsight.com/report-store/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Metastatic Pancreatic Cancer Treatment Analysis: Drug Profile
Motixafortide: BioLineRx
Motixafortide (formerly BL-8040/BKT140) is a selective inhibitor of the CXCR4 chemokine receptor, a well-established therapeutic target involved in the mobilization and trafficking of hematopoietic stem cells, immune cells, and cancer cells from the bone marrow and lymph nodes into peripheral blood. It is being developed for multiple uses, including mobilizing hematopoietic stem cells for autologous transplantation, treating solid tumors, and addressing various hematological malignancies.

Fuzuloparib: Jiangsu Hengrui Pharmaceuticals
Fuzuloparib is an orally active small-molecule PARP inhibitor developed by Jiangsu Hengrui Pharmaceuticals for solid tumors. Approved in China for ovarian cancer (including fallopian tube and primary peritoneal cancers), it is currently being evaluated in Phase II and III trials for additional solid cancers such as pancreatic, breast, prostate, and lung cancers.

Learn more about the novel and emerging metastatic pancreatic cancer pipeline therapies at https://www.delveinsight.com/report-store/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Metastatic Pancreatic Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous

By Molecule Type
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Metastatic Pancreatic Cancer Pipeline Report
• Coverage: Global
• Key Metastatic Pancreatic Cancer Companies: Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others.
• Key Metastatic Pancreatic Cancer Pipeline Therapies: Fuzuloparib, Glufosfamide - Eleison Pharmaceuticals, SBP 101, SGT-53, MDB 401 B, Motixafortide, Epacadostat, Retifanlimab, Roducitabine, Olaratumab, RX 0201, Masitinib, Simurosertib, and others.

To dive deep into rich insights for drugs used for metastatic pancreatic cancer treatment, visit: https://www.delveinsight.com/report-store/metastatic-pancreatic-cancer-mpc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Metastatic Pancreatic Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Metastatic Pancreatic Cancer Pipeline Therapeutics
6. Metastatic Pancreatic Cancer Pipeline: Late-Stage Products (Phase III)
7. Metastatic Pancreatic Cancer Pipeline: Mid-Stage Products (Phase II)
8. Metastatic Pancreatic Cancer Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.